Amgen starts two critical late-stage trials for weight loss drug MariTide

• 

  Novo’s Weight Loss Drugs Removed from FDA Shortage List

  The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list.
  
  Inc. - Feb. 22

• Healthy Returns: AbbVie is the newest potential weight loss drug market player

  AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS conference gets underway in Vegas.
  
  CNBC - 1d
• 

  Drug compounders sue over weight loss drugs' removal from FDA shortage list

  A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for removing semaglutide, the active ingredient in Ozempic, from its drug ...
  
  The Hill - Feb. 25

• From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugs

  Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
  
  CNBC - Feb. 20

• Why Walmart’s warning may have more to do with weight-loss drugs than tariffs

  Walmart’s stock fell Thursday as quarterly earnings were expected to decline for the first time in three years, with strength in groceries and GLP-1 drug sales continuing to pressure margins.
  
  MarketWatch - Feb. 21

• Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs

  Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended trading.
  
  CNBC - Feb. 24
• 

  We know so little about taking weight-loss drugs without prescription – is it really worth it? | Devi Sridhar

  Studies show that they’re effective for overweight people, but if you’re healthy, there are less risky ways to lose weight. When I’ve been in the gym over the past few months, one of the things ...
  
  The Guardian - Feb. 25

• Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access

  Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.
  
  CNBC - Feb. 25

• Eli Lilly cuts price of weight-loss drug Zepbound as competition heats up

  The drug company is calling on insurers and federal programs to cover obesity as a chronic disease.
  
  MarketWatch - Feb. 26

More from CNBC

• 'Tariff war, a trade war or any other type of war' — China says it's ready to fight U.S. until the end

  Beijing announced Tuesday additional tariffs as high as 15% on certain U.S. goods, starting from March 10 and a series of new export restrictions for designated U.S. entities.
  
  CNBC - 12m

• Amazon's cloud unit forms agentic AI group

  Swami Sivasubramanian, who has run Amazon Web Services' database business, will lead a new group focused on agentic AI.
  
  CNBC - 3h

• Japanese 10-year bond yields surge to near 16-year highs on rate-hike expectations, global sell-off

  The 30-year bond also crossed the 2.5% mark for the first time since 2008.
  
  CNBC - 7m

• Appeals court allows Trump administration to remove ethics watchdog Dellinger — for now

  The Supreme Court is likely to determine whether President Donald Trump can fire Hampton Dellinger as head of the Office of Special Counsel.
  
  CNBC - 2h

• MongoDB shares sink after company issues weak guidance

  MongoDB's earnings forecast for the 2026 fiscal year came in well below Wall Street expectations.
  
  CNBC - 3h

More in Business

• Japanese 10-year bond yields surge to near 16-year highs on rate-hike expectations, global sell-off

  The 30-year bond also crossed the 2.5% mark for the first time since 2008.
  
  CNBC - 7m

• 'Tariff war, a trade war or any other type of war' — China says it's ready to fight U.S. until the end

  Beijing announced Tuesday additional tariffs as high as 15% on certain U.S. goods, starting from March 10 and a series of new export restrictions for designated U.S. entities.
  
  CNBC - 12m
• 

  Trump hands carmakers 1-month reprieve from tariffs

  Carve-out applies to companies operating through US-Mexico-Canada trade pact
  
  Financial Times - 23m

• Trump hates the Biden-era Chips Act. What’s next for semiconductor makers?

  Intel is viewed as “being left on the side of the road” by the Trump administration.
  
  MarketWatch - 1h

• Why ‘Trump Turmoil’ has made a U.S. recession much more likely

  Instead of rapid-fire trade deals, Trump has triggered a trade war.
  
  MarketWatch - 1h